A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

Launched by INNOVENT BIOLOGICS (SUZHOU) CO. LTD. · Jul 25, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called IBI302 for people with a condition known as neovascular age-related macular degeneration (nAMD). This is a serious eye disease that can lead to vision loss. In this study, researchers will give participants an injection of IBI302 into the eye to see how effective it is in improving vision and whether it is safe to use. The trial is currently recruiting participants who are at least 50 years old and have specific types of eye problems related to nAMD.

To be eligible for the study, participants must sign a consent form and meet certain criteria, such as having active eye disease and a specific level of vision. Participants will receive treatment at a medical center and will be monitored closely throughout the trial. It's important to know that some people may not qualify due to other health issues or recent treatments. Overall, this study aims to provide valuable information that could help improve care for those with nAMD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Signed informed consent must be obtained prior to study participation;
• • 2. Male or female ≥ 50 years of age at the time of signing the informed consent;
• • 3. Active subfoveal CNV secondary to nAMD, or active CNV with intra/subretinal fluid involving the fovea;
• • 4. BCVA of 19 to 78 ETDRS letters (inclusive) in the study eye at baseline.
• Exclusion Criteria:
• 1. Ocular disease:
• • Any concurrent intraocular condition/systemic disease in the study eye at screening or baseline that, in the judgment of the investigator, may cause the participant fail to respond to the treatment or confuse the interpretation of study results;
• • Total lesion area(including blood, atrophy, fibrosis, PED and neovascularization)\> 12 optic disc area (DA) on FFA;
• • Subretinal hemorrhage area \> 50% of the total lesion area, or subretinal hemorrhage area involving macular fovea ≥ 1 DA;
• • Fibrosis or atrophy area \> 50% of the total lesion area, or involving the fovea; Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg after standard treatment);
• • Presence of active intraocular or periocular infection or inflammation;
• 2. Ocular treatment:
• • Anti-VEGF or anti-complement therapy in the study eye within 90 days prior to baseline;
• • Fundus laser photo-coagulation in the study eye within 90 days prior to baseline;
• • Photodynamic Therapy (PDT) in the study eye within 90 days prior to baseline;
• • History of vitreoretinal surgery, penetrating keratoplasty in the study eye;
• 3. General condition or treatment:
• • Uncontrolled hypertension (defined as systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg after standard treatment);
• • HbA1c \> 8% within 28 days prior to baseline; Systemic anti-VEGF drug and anti-complement drug therapy within 90 days prior to baseline;
• • History of hypersensitivity to any component of the test article, control article, or clinically relevant sensitivity to fluorescein dye, povidone-iodine;
• • Pregnant or lactating women; Inappropriate for the study (e.g., substance abuse, inability or unwillingness to follow the trial protocol), as judged by the investig.